3-Ethynylaniline CAS 54060-30-9 Puritas >99.0% (GC)

Description:

Chemical Name: 3-Ethynylaniline

Synonyma: 3-Aminophenylacetylene

CAS: 54060-30-9

Puritas: >99.0% (GC)

Aspectus: lux Yellow ut Brown Liquid

Medium Hydrochloridis Erlotinib (CAS: 183319-69-9)

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Ducens fabrica et supplementum de Hydrochloride Erlotinib intermedia
Erlotinib Hydrochloridis CAS 183319-69-9
3-Ethynylaniline CAS 54060-30-9
6,7-Bis(2-Methoxyethoxydorum) -3H-Quinazolin-4-unum CAS 179688-29-0
Please contact: alvin@ruifuchem.com

Chemical Properties:

Nomen chemicum	3-Ethynylaniline
Synonyma	3-Aminophenylacetylene
CAS Number	54060-30-9
CATTUS Number	RF-PI2241
Stock Status	In Stock, Productio Capacitas 50MT/Mense
Formulae hypotheticae	C8H7N
M. Pondus	117.15
Sensitiva	Aer Sensitiva, lux sensitiva
Ferveret	120℃/20 mmHg
Aqua Solubility	Insolubilis in aqua
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Lux Yellow ut Brown Liquid
Puritas / Analysis Methodus	>99.0% (GC)
Aquae Caroli Fischer	<0.50%
Residere in Ignition	<0.20%
Totalis immunditias	<1.00%
Gravitas Imprimis (20/20℃)	1.041~1.048
Index refractivus n20/D	1.614~1.6195
Infrared Imaginis	Conformat ut Structure
Proton NMR Spectrum	Conformat ut Structure
Test Standard	Enterprise Standard
Consuetudinem	Pharmaceutical Medium;Erlotinib Hydrochloride media

Sarcina & Repono:

sarcina: Fluorinated Utrem, 25kg/Drum, vel secundum exigentiam mos

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

Applicatio:

3-Aminophenylacetylene (CAS: 54060-30-9) adhibetur ut intermedium pharmaceuticum.3-Ethynylaniline medium est Hydrochloridi Erlotinib (CAS: 183319-69-9).Hydrochloridis erlotinib est parvum inhibitoris kinasi moleculae tyrosinae, quae convertibiliter agit in receptoribus epidermalibus incrementis, hydrochloride de erlotinib, medicamento hypothetico-iscopato.US cibum et medicamentum Administrationis (FDA) approbavit erlotinib (Tarceva) cum gemcitabine coniunctum sicut curationem primi rectam ad cancer localiter progressus et metastaticus pancreaticus.Praecipue adhibetur ut curatio secunda vel tertia linea pro progresso vel metstatico non-miniculo cancer pulmonis cellulae (NSCLC) et sicut curatio cancer pancreatici.Adhibetur ut inhibitor tyrosinus pro NSCLC curationis.Erlotinib hydrochloride quinazolineum parvum moleculum inhibitoris incrementi epidermalis receptoris (EDGFR) tyrosini kinasis derivatum, mense Novembri anno 2004 probatum est, in curatione cancri pulmonis non parvae metastaticae vel metastaticae.